Determination of Regulatory Review Period for Purposes of Patent Extension; BEQVEZ
Published Date: 2/6/2026
Notice
Summary
The FDA has set the official review period for BEQVEZ, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind BEQVEZ and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s effort during review, you have until early August 2026 to speak up—no money changes hands now, but this could impact how long the patent lasts.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Sets BEQVEZ Review Period
FDA determined the regulatory review period for BEQVEZ is 3,277 days total — 2,913 days in the testing phase and 364 days in the approval phase. Key dates used were: IND effective May 8, 2015; biologics license application initially submitted April 28, 2023; and approval on April 25, 2024. This FDA determination establishes the maximum potential patent-extension period; the patent applicant is seeking 671 days of patent term extension and the USPTO will apply statutory limits in its final calculation.
Deadlines to Challenge BEQVEZ Dates
If you believe the published dates are incorrect, you must submit comments asking for a redetermination by April 7, 2026. Any interested person may petition FDA to determine whether the applicant acted with due diligence during the regulatory review period by August 5, 2026; petitions must meet the requirements of 21 CFR 60.30 and be served on the patent applicant.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16939, GNT USA, LLC.; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by GNT USA, LLC., c/o Exponent, Inc., proposing that we amend our color additive regulations to provide for the safe use of safflower (Carthamus tinctorius L.) extract as a color additive in various foods at levels consistent with good manufacturing practices.
2026-16942, Food Additives Permitted in Feed and Drinking Water of Animals; Chromium DL-methionine Chelate
The Food and Drug Administration (FDA, we, or the Agency) is amending the regulations for food additives permitted in feed and drinking water of animals to provide for the safe use of chromium DL- methionine chelate as a nutritional source of chromium in cattle feed. This action is in response to a food additive petition filed by Zinpro Corp.
2026-16944, Gardenia Blue Interest Group; Filing of Color Additive Petition
The Food and Drug Administration (FDA or we) is announcing that we have filed a petition, submitted by Gardenia Blue Interest Group (GBIG or petitioner), c/o Exponent, Inc., proposing that we amend our color additive regulations to expand the safe use of gardenia (genipin) blue in various foods at levels consistent with good manufacturing practice. The petition also proposes to lower the specification for arsenic in gardenia (genipin) blue.
Previous / Next Documents
Previous: 2026-02386, Agency Information Collection Activities; Proposed Collection; Comment Request; Expedited Programs for Serious Conditions-Accelerated Approval of Drugs and Biologics
The FDA wants your thoughts on how it collects info about speeding up drug and biologic approvals for serious illnesses. This affects drug makers and patients waiting for faster access to important treatments. You’ve got until April 7, 2026, to share your comments—so don’t miss out on shaping the future of faster medicine approvals!
Next: 2026-02388, Determination of Regulatory Review Period for Purposes of Patent Extension; COBENFY
The FDA has set the official review period for COBENFY, a human drug, so its patent holder can apply for extra patent time. This affects the drug company and anyone tracking patent protections, with deadlines to challenge dates or diligence claims by April 7 and August 5, 2026. It’s a key step to help the company protect its invention longer, potentially impacting when generic versions can enter the market.